Biogen to share long-term trial results for its Alzheimer’s drugs
Biogen will present new data across its Alzheimer’s disease portfolio at the 19th Clinical Trials on Alzheimer’s Disease conference, 16–19 November 2026, in Boston. Presentations will include expanded results from the Phase 2 CELIA study of diranersen (BIIB080), with a late-breaking symposium report
<p>Biogen will present new data across its Alzheimer’s disease portfolio at the 19th Clinical Trials on Alzheimer’s Disease conference, 16–19 November 2026, in Boston. Presentations will include expanded results from the Phase 2 CELIA study of diranersen (BIIB080), with a late-breaking symposium report</p>